These new investors join the dream team that CRISPR Therapeutics has put together, which include Versant Ventures (one of the biggest Biotech VCs out there) as the founding investor, Celgene, GSK (through SR One) and Abingworth (a top European VC).

Some of the investors in CRISPR Therapeutics.

Then there are the other investors in this Series B round: Vertex Pharmaceuticals (who signed a €2.29Bn deal) and Bayer Global Investments, which was part of its €275M collaboration. In the end, this long Series B has raised over €126M ($140M). It should be enough for some time and to postpone the need to IPO (as Editas and Intellia did).

Feature Image Credit: Leaf cutting ants at the London Butterfly House in Syon Park (CC 2.0 William Warby)

Labiotech.eu is the leading digital media covering the European Biotech industry. Over 75,000 monthly visitors use it to keep an eye on the business and innovations in biotechnology. Hope you'll enjoy reading our stories!